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ABSTRACT 
The mechanism of action of a relatively new antipsychotic drug-Risperidone differs from 
conventional antipsychotics like Haloperidol. We compared low dosages of Risperidone with near 
equivalent dosages of Haloperidol in first episode drug naive Acute and Transient Psychotic disorder. 
A single blind randomised four-week study protocol was employed. Highly significant and comparable 
efficacy as assessed by Brief Psychiatric Rating Scale and Global Assessment of Functioning 
Scale was seen at the end of the Study protocol in both the groups. Risperidone had significantly, 
an early onset of action on some of the positive as well as negative symptoms with less incidence 
of Extrapyramidal Symptoms in comparison to Haloperidol. We conclude that Risperidone may 
represent a potential useful first line agent in the treatment of Acute and Transient Psychotic Disorder. 
Key words: Risperidone in first episode psychosis, risperidone, haloperidol, acute and transient 
psychotic disorder. 
Leysen et al (1988) and Janssen et al., 
(1988) reported that Risperidone strongly 
antagonize central serotonin 5 - HT2 receptors 
and Dopamine D2 receptors, whereas 
conventional antipsychotics such as Haloperidol 
more strongly antagonize D2 and only weakly 
block 5HT receptors. 
Adityanjee et al. (1995) found encouraging 
preliminary results in the use of Risperidone in 
first episode Schizophrenia & provided some 
support for the early use of Risperidone. 
According to Kopala (1997), recent clinical 
experience in Canada has shown that 
Risperidone is effective in the treatment of 
patients with first episode Psychosis and with 
the further accumulation of data, the mean daily 
dose of Risperidone required by first episode 
patients was shown to be close to 4mg. 
According to Lieberman etal.(1993) and McEvoy 
et al.(1991) first episode patients have better 
therapeutic responses to antipsychotic drug 
treatment, and are more sensitive to develop 
EPS and require lower doses of medications. 
Johnson (1995) reported that although the 
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third consensus conference on methodology of 
clinical trials of antipsychotics had concluded that 
the optimal duration of short term trials is 
between 4-8 weeks, it can only indicate a very 
preliminary & tentative outcome unless it is in 
individuals who had been previously drug free. 
According to Kane (1994), the data from 
multicentre trials suggest a bimodal response 
pattern, wherein the 6 mg and 16 mg dose of 
Risperidone are most effective. Buckley (1997) 
reported that the modal dose of Risperidone in 
clinical practice in the united states is 4.6 mg daily. 
Danik & Goverdhan (1963); Mountain 
(1963) have reported success with use of high 
dosages of haloperidol in the acutely Psychotic 
patients, while Fitzgerald (1969) & Anderson et 
al. (1976) had all reported high improvement 
rates with low dosages of Haloperidol in the 
acutely ill Psychotic patients. 
Khannaetal. (1997) in an Indian trial with 
low & high dosages of haloperidol on a sample 
of Acute & transient Psychotic disorders (ICD-
10) did not report any significant difference in 
the improvement rate between the two groups. RISPERIDONE VS. HALOPERIDOL IN ACUTE PSYCHOTIC DISORDERS 
According to Kammen and Marder (1995), 
0.6 mg of Risperidone is equivalent to 100 mg 
of Chlorpromazine & 2 mg of haloperidol is 
equivalent to 100 mg of Chlorpromazine. 
The aim of the present study is to compare 
4 mg of Risperidone (RIS) with near equivalent 
doses of Haloperidol (HAL) for outcome of 
clinical symptomatology at short term in first 
episode drug naive acute & transient Psychotic 
disorder (F23, ICD-10). 
MATERIAL AND METHOD 
The study group consisted of indoor 
patients in the department of Psychiatry at 
Gauhati Medical College and Hospital, Guwahati. 
Subjects were diagoned as per 
International Classification of Disease - 10 
criteria for acute and transient psychotic disorder 
(F23). The diagnosis of the cases were reviewed 
by the senior consultant after the initial workup 
of the patients by the Post-Graduate residents 
in the department of Psychiatry. 
The sample for the study consisted of 
subjects who fulfilled the following : 
Selection criteria : (1) Age between 16 and 55 
years, (2) Patients in the first episode of the 
disorder, (3) Patients who were free from 
antipsychotic drug treatment prior to the period 
of initial assessment, (4) No past history of any 
Psychiatric morbidity. 
The exclusion criteria are the following : 
(1) Severe medical illness i.e., presence of any 
physical disorders requiring active medication, 
or pregnancy & lactation, (2) Patients having 
neuropsychiatric illness such as epilepsy, mental 
retardation, drug-induced psychosis, substance 
abuse disorder, etc. (3) Other psychiatric illness 
such as bipolar disorder, schizophrenia, etc. 
The patients fulfilling the selection criteria 
were randomly assigned to either risperidone 4 
mg (equivalent to 666.67 mg of chlorpromazine) 
or haloperidol 15 mg (equivalent to 750 mg of 
chlorpromazine) in a single blind four week 
protocol. They were administered the semi-
structured proforma of Brief Psychiatric rating 
Scale (Overall et al.,1962) at Day 0, Day 7, Day 
14 and Day 28. The dimension of 
psychopathology was interpreted by scoring 
subjects on the four BPRS factors (Overall & 
Gorham,1962) viz. (1) THINKING 
DISTURBANCE (consist of conceptual 
disorganization, hallucinatory behaviour, unusual 
throught content). (2) HOSTILE 
SUSPICIOUSNESS (consist of items hostility, 
suspiciousness and unco-operativeness). (3) 
WITHDRAWAL RETARDATION (consist of 
emotional withdrawal, motor retardation, blunted 
affect). (4) ANXIOUS DEPRESSION (consist of 
anxiety, guilt, depression). 
A high inter-rater reliability was achieved 
in the administration of the BPRS (correlation 
co-efficient r=1) prior to the onset of the protocol. 
Similarly the Global Assessment of 
Functioning Scale (GAF) was administered at 
Day 0, Day 7, Day 14 and Day 28. 
The subjects were also assigned oral 
trihexiphenidyl 6 mg for extrapyramidal 
symptoms (EPS), and lorazepam 2 mg. at 
bedtime, if required for sedation, which were duly 
recorded in each case. 
Statistical analysis : Carried out by using the 
Paired *t' test and Fisher's t test. 
RESULTS 
Thirty-five patients gave full informed 
consent and were included in the study (HAL 
group=18 & RIS group=17). Five patients 
dropped out of the study prior to completion of 7 
days of protocol. Thus thirty patients completed 
the 4-week study protocol (HAL=15 & RIS = 15). 
Table 1 sh<?ws the Distribution of socio-
demographic variables in the Haloperidol & 
Risperidone groups Results indicate no major 
difference in the distribution of diagnostic 
categories between the two groups a,id the 
majority had acute schizophrenia like psychotic 
disorders (Table 2). Results on comparision of 
clinical variable between the two groups indicate 
no difference in the duration of illness prior to 
initial assessment ; no major difference in 
distribution of precipitating factors in the three 
months preceding the onset of illness; and no 
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TABLE 1 
DISTRIBUTION OF SOCIODEMOGRAPHIC VARIABLES 
IN HALOPERIDOL & RISPERIDONE GROUPS 
Socio-
demographic 
variables 
Aae(vrs) 
16-25 
26-35 
36-45 
46-55 
Sex 
Male 
Female 
Educational level 
Illiterate 
Upto primary level 
Upto high school 
College level 
Occupational status 
Student 
Unemployed 
Daily Wage Earner 
House Wife 
Cultivator 
Skilled labourer 
Business 
Marital status 
Married 
Unmarried 
Widowed 
Socio-economic status 
(Rs. per month) 
< 1500 pm. 
1500-3000 
&less 
3000 - 4500 
&less 
4500 & above 
Place of locality 
Rural 
Urban 
Semi-Urban 
Haloperidol 
(n=15) 
13(86.6) 
2(13.3) 
0 
0 
8(53.3) 
7(46.6) 
4(26.6) 
3(20) 
6(40) 
2(13.3) 
5(33.3) 
3(20) 
1 (6.6) 
2(13.3) 
2(13.3) 
1 (66) 
1 (6.6) 
4(26.6) 
11 (73 3) 
Nil 
12(80) 
3(20) 
Nil 
Nil 
12(80) 
2(13 3) 
1 (6.6) 
Risperidone 
(n=15) 
11 (73.3) 
3(20) 
0 
1 (6.6) 
7 (46.6) 
8(53.3) 
0 
4(26.6) 
10(66.6) 
1 (6.6) 
6(40) 
6(40) 
2(13.3) 
1 (6.6) 
Nil 
Nil 
Nil 
Nil 
14(93.3) 
1 (66) 
9(60) 
2(13.3) 
Nil 
4(26.6) 
12(80) 
3(20) 
Nil 
TABLE 2 
DISTRIBUTION OF DIAGNOSTIC CATEGORIES 
(ICD-10) AND CLINICAL VARIABLES IN 
RISPERIDONE & HALOPERIDOL GROUPS 
Figure in parenthesis indicate percentage 
major difference in the distribution of family 
history of psychosis (Table 2). 
Results on comparison for use of adjunct 
medications between HAL group & RIS group 
indicate that all subjects (15 or 100%) in HAL 
group required trihexiphenidyl, whereas only 6 
(40%) in the RIS group required it by the end of 
the fourth week of protocol. The results also 
indicate that more subjects in the RIS group 
required lorazepam (for sedation), propranolol (for 
akathisia) & parenteral diazepam when compared 
Diaqnostic 
cateaories 
F23.0 
Acute polymorphic 
psychotic disorder 
without symptoms 
of schizophrenia 
F23.2 
Acute schizophrenia 
like psychotic 
disorder 
F23.8 
Other acute & 
transient psychotic 
disorders 
Clinical variables 
(A) Duration of illness 
before assessment 
(in days) 
Upto 7 
8-15 
16-30 
(B) Precipitating factors 
(in preceding 3 months) 
Present 
Absent 
(C) Family history of 
psychosis (first and 
second degree relative) 
Present 
Absent 
Haloperidol 
group ( 
n 
1 
9 
5 
9 
5 
1 
7 
8 
6 
9 
i=15) 
% 
6.6 
60 
33.3 
60 
33.3 
6.6 
46.6 
53.3 
40 
60 
Risperidone 
group (n 
n 
Nil 
9 
6 
9 
5 
1 
5 
10 
7 
8 
=15) 
% 
-
60 
40 
60 
33.3 
6.6 
33.3 
66.3 
46.6 
53.3 
with those in the HAL group (Table 3). 
Result (Table 4) on analysis of BPRS for 
changes in score between respective days of 
assessment in HAL group & RIS group, show 
that the rate of improvement is highly significant 
(p<0.001) between day 0-7; day 0-14; & day 
0-28. In the HAL group the rate of improvement 
is more significant in the first two weeks 
(p<0.001) than the last two weeks (p<0.05). In 
the RIS group, the rate of improvement in the 
frst two weeks and the last two weeks are equally 
significant (p<0.001). On analysis, results on 
GAF scale (Table 4) indicate that in both the 
groups, the rate of improvement of global 
fuctioning between day 0 & 7, day 0 & 14, day 0 
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TABLE 3 
COMPARISON IN USE OF ADJUNCT MEDICATIONS BETWEEN HALOPERIDOL & RISPERIDONE GROUPS 
Medication 
Trihexyphenidyl 
(fixed dose - 6 mg 
for EPS) 
Tab Lorazepam 
2mgHS 
(for sedation) 
Propranolol 
40 mg (fixed dose) 
(for Akithisia) 
Inj. Diazepam 
20mg(SOS) 
Haloperidol Group 
n= 
1stwk 
4 
(26.67) 
7 
(46.6) 
Nil 
10 
(66.6) 
=15 
2ndwk 
(+3) 
7 
(46.6) 
7 
(46.6) 
Nil 
5 
(33.3) 
3rdwk 
(+7) 
14 
(93.3) 
7 
(46.6) 
Nil 
2 
(13.3) 
4thwk 
(+D 
15 
(100) 
7 
(46.62) 
Nil 
1 
(6.6) 
1st wk 
Nil 
10 
(66.6) 
Nil 
12 
(80) 
Risperidone Group 
n=15 
2ndwk 
(+3) 
(20) 
9 
(60) 
Nil 
7 
(46.6) 
3rdwk 
(+3) 
6 
(40) 
9 
(60) 
2 
(13.3) 
2 
(13.3) 
4th wk 
Nil 
6 
(40) 
9 
(60) 
(+2) 
4(26.6) 
1 
(6.6) 
% in parenthesis. 
TABLE 4 
COMPARISON OF CHANGES IN (a) B.P.R.S. (b) G.A.F. SCORES BETWEEN RESPECTIVE DAYS OF 
ASSESSMENT IN HALOPERIDOL & RISPERIDONE GROUPS 
DayO 
Mean SD 
(a)80.7±32.46 
(b)25.66±4.5 
DayO 
(a) 60.7±32.46 
(b) 25.6614.5 
DayO 
(a) 80.7t32.46 
(b) 25.6614.5 
Day 7 
(a)56.53±26.16 
(b)38 4±10.09 
Day 7 
(a)56 53±26.16 
(b)33.4±10.09 
Day 14 
(a) 45 26127 55 
(b)53 2i17.1 
Haloperidol group 
Day 7 
Mean SD 
56.53l26.16 
38.4H0.09 
Day 14 
45.26i27.55 
53.2H7.1 
Day 28 
30*10.15 
59.2119.6 
Day 14 
4526127.55 
53.2H7.1 
Day 28 
30H0.15 
59.2H9.6 
Day 28 
3O±10.15 
592119.6 
t 
(p value) 
4.8892 (p<0.001) 
4.8375 (p<0.001) 
t 
(p value) 
5.7488 (p<0.001) 
6 4104(p<0.001) 
t 
(p value) 
5.579 (p<0.001) 
7.2847 (p<0.001) 
t 
(p value) 
5 0763(p<0 001) 
7 2422(p<0.001) 
t 
(p value) 
4.1822(p<0.001) 
7.518 (p<0.001) 
t 
(p value) 
2.7718 (p<0 05) 
4.1936 (p<0.001) 
Risperidone group 
DayO 
Mean SD 
81.46±26.41 
23.86±4.5 
DayO 
81.46±26.41 
23.88±4.5 
Day 7 
81.46±26.41 
23.86±4.5 
Day 7 
46±1715 
38.4t12.06 
Day 7 
46±17.15 
38.4±12.06 
Day 14 
30.73±7 
55.6±16 
Day 7 
Mean SD 
46.00±17.15 
38.4±12.06 
Day 14 
30.73±7 
55.6±16 
Day 28 
27.2110.6 
70.8±21.8 
Day 14 
3073±7 
55 6116 
Day 28 
27.2H0.6 
70.8121.8 
Day 28 
27 2110.6 
708*218 
t 
(p value) 
5.7185 (p<0 001) 
5.1582 (p<0.001) 
t 
(p value) 
7.831 (p<0.001) 
8.9435 (p<0.001) 
t 
(p value) 
6 8952(p<0.001) 
8.7442 (p<0.001) 
t 
(p value) 
5 2035(p<0.001) 
6 2035(p<0 001) 
t 
(p value) 
4.7587 (p<0.001) 
8.1424 (p<0.001) 
t 
(p value) 
5.6775 (p<0.001) 
5.9369 (p<0 001) 
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TABLE 5 
COMPARISON OF SCORE BETWEEN HALOPERIDOL 
GROUP AND RISPERIDONE GROUP AT RESPECTIVE 
DAYS OF ASSESSMENT (a) BPRS & (b) GAF 
Fishers t' test 
Day of 
assessment 
DayO 
Day 7 
Day 14 
Day 28 
Halopendol 
(n=15) 
Mean SD 
(a)80.7±32.46 
(b)25.66±4.5 
(a)56.53±26.16 
(b)38.4±10.09 
(a)45.26±27.5 
(b)53.2±17.1 
(a) 30. ±10.15 
(b)59.2±19.6 
Risperidone 
(n=15) 
MeanSD 
81.46±26.41 
23.86±4.53 
46±17.15 
38.4±12.06 
30.73±7 
556±16 
27.2±10.6 
70.8±21.8 
t 
(p value) 
0.0706 
p>0.05 
1.125 
p>0.05 
1.3113 
p>0.05 
0 
p>0.05 
1.9904 
p>0.05 
0.398 
p>0.05 
0.7368 
p>0.05 
1.5466 
p>0.05 
d.f.=28, p>0.05, not significant 
& 28, & day 14 & 28 were significant (p<0.001). 
Table 5a, shows comparison of BPRS 
score between the two groups at respective days 
of assessment and indicate no significant 
difference in lowering of BPRS scores at day 0, 
7,14 & 28 (p<0.05). Similarly comparison of GAF 
score (Table 5) indicate no significant difference 
in the increase of scores between both the groups 
at day 0, 7, 14 & 28 (p>0.05). 
Comparison of scores (Table 6) between 
HAL group & RIS group at respective days of 
assessment indicate that at day 14, the score on 
THINKING DISTURBANCE in RIS group is 
significantly lower than that of HAL group (p<0 05); 
At day 14, the score on HOSTILE 
SUSPICIOUSNESS in RIS group is significantly 
lower than that of HAL group (p<0.05); At day 7, 
WITHDRAWAL RETARDATION in the RIS group 
is significantly lower than that of HAL group 
(p<0.05); whereas at day 0,7,14 & 28, the analysis 
of ANXIOUS-DEPRESSION show no significant 
difference between the two groups (p>0.05). 
Kdsults from (Table 6) show change in 
score between respective days of assessment 
in HAL group and RIS group which indicate that 
for THINKING DISTURBANCE, in HAL group, 
the rate of improvement between day 0 & 7, day 
0 & 14, day 0 & 28 is highly significant (p<0.001). 
The rate of improvement in the first two weeks 
being more significant (p<0.001) than the last 
two weeks of protocol (p<0.05). In RIS group, 
rate of improvement between day 0 & 7, day 0 
& 14, day 0 & 28 is highly significant (p<0.001). 
The rate of improvement in first two weeks is 
highly significant (p<0.001), but there is no 
further significant improvement during the last 
two weeks of protocol (p>0.05) ; Analysis of 
HOSTILE SUSPICIOUSNESS indicate that both 
HAL group & RIS group have similar results. 
Improvement is highly significant between day 
0 & 7, day 0 & 14, day 0 & 28 (p<0.001). Rate of 
improvement between day 0 & 7 is more 
significant (p<0.001) than between day 7 & 14 
(p<0.01) & rate of improvement between day 0 
& 14 is more significant (p<0.001) than between 
Day 14 & 28 (p<0.05). Analysis of 
WITHDRAWAL RETARDATION indicate that in 
HAL group there is significant worsening between 
day 0 & 7 (p<0.001) and also between day 0 & 
14 (p<0.05). But there is significant improvement 
between day 0 & 28 (p<0.05). The rate of 
improvement in first two weeks is less significant 
(p<0.05) than that during the last two weeks of 
protocol (p<0.01), in the RIS group the rate of 
improvement is significant between day 0 & 7, 
day 0&14, day 0&28 (p<0.01). The rate of 
improvement between day 0 & 7 & day 7 & 14, 
day 0 & 14 & day 14 & 28 are all similarly 
significant (p<0.01); Analysis of ANXIOUS 
DEPRESSION indicate that in HAL group the 
rate of improvement is significant between day 
0 & 7, (p<0.01), day 0 & 14 (p<0.05), day 0 & 28 
(p<0.05) day 7 & 14 (p<0.05) & day 14 & 28 
(p<0.05), whereas in RIS group the rate of 
improvement is highly significant (p<0.001) 
between day 0 & 7, day 0 & 14, day 14 & 28 & 
day 0 & 28. Significant improvement is also seen 
between day 7 & 14 (p<0.01). 
Table 7, indicate comparison of scores 
between both groups, for individual items at 
respective days of assessment. The results 
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TABLE 6 
COMPARISON IN SCORES OF DIMENSIONS OF PSYCHOPATHOLOGY (A) AT RESPECTIVE 
DAYS OF ASSESSMENT & (B) BETWEEN RESPECTIVE DAYS OF ASSESSMENT 
Dimensions of 
psychopathology 
(a) Thinking 
disturbances 
(b) Hostile 
A - At respective days of assessment 
(Fishers t'test d.f =28) 
Days of 
assess-
ment 
0 
7 
14 
28 
0 
7 
suspiciousness 
(c) Withdrawal 
retardation 
(d) Anxious 
depression 
14 
28 
0 
7 
14 
28 
0 
7 
14 
26 
Haloperidol 
group(n=15) 
Mean SD 
5.42*2.09 
3.63*2.5 
2.56*2.03 
1.88*1.2 
4.49*1.9 
3.05*2.3 
2.6*2.1 
1.25*0 5 
1.85*1.54 
2.45*1.2 
1.99*1.15 
1.35*0.4 
3.86*2.6 
3.44*2.4 
2.45*1.9 • 
1.61*0.7 ' 
Risperidone 
group(n=15) 
Mean SO 
5.46*2 06 
3.15*1.1 
1.32*0.5 
1.26*0.5 
4.04*2.1 
2.14*1.1 
1.43*0.66 
1.37*1.1 
187*1.07 
1.68*0.7 
1.63*0.6 
1.29*0 3 
4.09*1.9 
2.33*12 
1.62*0.5 
1.49*0 8 
t' 
(p value) 
0.0526 
<p>0.05) 
0.6 
(p>0.05) 
2.2962 
(p<0.05) 
1.771 
(p>0.05) 
0.803 
(p>0.05) 
1.34 
(p>0.05) 
2.0526 
(p<0 05) 
0.3636 
(p>0.05) 
0.04 
p>0.05 
2.1388 
p<0.05 
1.03 
p>0.05 
0.43 
p>0.05 
0.27 
p>0.05 
159 
p>0.05 
1.6 
p>0.05 
043 
p>0.05 
B-Between respective days of 
assessment (Paired "f testd.f.=14) 
Days of 
assess-
ment 
Day 0 & 7 
Day0 8<14 
Day 0 & 28 
Day 7 & 14 
Day 14 & 28 
Day 0 & 7 
Day0&14 
Day0&28 
Day 7 & 14 
Day 14 & 28 
Day 0 & 7 
Day0&14 
Day0&28 
day7&14 
Day 14 & 28 
Day 0 & 7 
Day0&14 
Day0&28 
Day 7 & 14 
Day 14 & 28 
Haloperidol 
"f 
(p value) 
4.68 
p<0.001 
5.72 
p<0.001 
5.92 
p<0.001 
4.23 
p<0.001 
2.36 
p<0 05 
6.31 
p<0.001 
4.24 
p<0.001 
5.91 
p<0.001 
2.93 
p<0.01 
2.92 
p<0.05 
3.50 
p<0.01 
2.87 
p<0 05 
2.88 
p<0.05 
4.547 
p<0.001 
3.07 
p<0.01 
3.31 
p<0.01 
2.76 
p<0.05 
327 
p<0 05 
311 
p<0 05 
2.59 
p<005 
Risperidone 
"f 
(p value) 
5.31 
p<0.001 
7.34 
p<0.001 
7.32 
p<0.001 
4.51 
p<0.001 
1.83 
p>0.05 
4.41 
p<0.001 
5.09 
p<0.001 
6.91 
p<0 001 
3.40 
p<0.05 
285 
p<0.05 
336 
p<0.01 
3.53 
p<001 
2.93 
p<0.01 
3.76 
p<0.01 
3.11 
p<0.01 
4.63 
p<0.001 
5.62 
p<0 001 
5.26 
p<0 001 
333 
p<001 
4.93 
p<0.001 
in RIS group at day 14 are more significantly 
improved (p<0.05) than those in HAL group; for 
hostility subjects in RIS group at day 7 are 
significantly more improved (p<0.01) than those 
in HAL group; For SUSPJCIOUSNESS subjects 
in RIS group at day 14 are significantly (p<0.05) 
more improved than those in HAL group. For 
EMOTIONAL WITHDRAWAL subjects in RIS 
group at day 7 are significantly better off (p<0.05) 
than those in HAL group; For MOTOR 
RETARDATION the scores in RIS group at day 
7, are significantly (p<0.05) lower than those 
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TABLE 7 
COMPARISON IN SCORES OF INDIVIDUAL ITEMS (A) AT RESPECTIVE 
DAYS 81 (B) BETWEEN RESPECTIVE DAYS OF ASSESSMENT 
Individual items in 
the dimensions of 
psychopa thology 
(from BPRS) 
Hallucinatory 
behaviour 
Hostility 
Suspiciousness 
Emotional 
withdrawal 
Motor 
retardation 
Anxiety 
Guilt 
Conceptual 
disorganization 
(a) At respective days of assessment 
(Fishers 
Days of 
assess-
ment 
0 
7 
14 
28 
0 
7 
14 
28 
0 
7 
14 
28 
0 
7 
14 
28 
0 
7 
14 
28 
0 
7 
14 
28 
0 
7 
14 
28 
0 
7 
14 
28 
0 
t'testdf.=28) 
Haloperidol 
group(n=15) 
Mean SD 
5.86i2.5 
3.812.7 
2.9±2.5 
2.2H.8 
4.3±3.1 
306l3.1 
2212.7 
1.13±0.5 
6.3312.3 
4.212.7 
3.812.3 
1.66H.02 
2.07H.9 
2.4±1.1 
1.6±0.9 
110 
1.67H.6 
2.47H.5 
2.27H.2 
1.610.9 
5.212.1 
3.7312.06 
2.67H.3 
1.811.3 
3.613.5 
. 3.613.5 
2.4712.7 
1.2710.4 
5.211.9 
3.212.4 
2.411.8 
1.510.9 
5.212.5 
Risperidone 
group (n= 15) 
Mean SD 
6.212.3 
3.311.7 
1.2710.5 
1.2911 
3.812.9 
1.611.05 
1.1310.3 
1.4H.05 
6.612.8 
3.211.8 
2.2H.6 
1.73H.5 
2.411.8 
1.5310.7 
1.3310.2 
1.0710.2 
1.2710.5 
1.610.75 
1.7310.7 
1.4710.6 
3.7310.1 
3.33H.3 
2.47H.1 
1.87H.3 
5.6713.7 
2.0712.3 
1.1310.5 
1.27H.03 
4.411.6 
2.6H.5 
2.4710.8 
1.210.8 
5.813.2 
'f 
(p value) 
0.39(p>0.05) 
0.60(p>0.05) 
2.41 (p<0.05)* 
1.65 (p>0.05) 
044 (p>0.05) 
3.90(p<0.05)* 
1.48(p>0.05) 
0.90(p>0.05) 
0.28 (p>0.05) 
2.01 (p>0.05) 
2.13(p<0.05)* 
014(p>0.05) 
0.49 (p>0.05) 
2.35(p<0.05)* 
0.96 (p>0.05) 
1.4(p>0.05) 
0.87 (p>0.05) 
2.12(p<0.05)* 
1.5(p>0.05) 
0.46(p>0.05) 
2.13(p<0.05)" 
0.63(p>0.05) 
0.44 (p>0.05) 
0.14(p>0.05) 
4.93 (p<0.05)* 
1.40(p>0.05) 
1.84(p>0.05) 
0(p>0.05) 
1.33(p>0.05) 
0.81 (p>0.05) 
1.79(p>0.05) 
1 (p>0.05) 
0.29(p>0.05) 
(b) Between respective days of 
assessment (Paired "f test d.f 
Days of 
assess-
ment 
Day 0 & 7 
Day0&14 
Day 0 & 28 
Day 7 & 14 
Day 7 & 28 
Day 14 & 28 
Day 0 & 7 
Day 0 8.14 
Day 0 & 28 
Day 7 & 14 
Day 7 & 28 
Day 14 & 28 
Day 0 & 7 
Day0&14 
Day 0 & 28 
Day 7 & 14 
Day 7 & 28 
Day 14 & 28 
Day0&7 
Day0&14 
Day 0 & 28 
Day 7 & 14 
Day 7 & 28 
Day 14 & 28 
Day0&7 
Day0&14 
Day0&28 
Day 7 8114 
Day 7 & 28 
Day 14 & 28 
Day 0 & 7 
Day0&14 
Day 0 & 28 
Day 7 & 14 
Day 7 & 28 
Day 14 & 28 
Day0&7 
Day0&14 
Day 0 & 28 
Day 7 & 14 
Day 7 & 28 
Day 14 & 28 
Haloperidol 
"f 
(p value) 
4.33(p<0.001) 
5.08(p<0.001) 
4.86(p<0.001) 
5.46(p<0.001) 
4.57 (p<0 001) 
2 0824(p>0 05) 
3.03(p<0.01) 
3.48(p<0.01) 
3.89(p<0.01) 
1.93(p>0.05) 
2.572 (p<0.05) 
1.85(p>0.05) 
=14) 
Resperidone 
"f 
(p value) 
5.47(p<0.001) 
7.83(p<0.001) 
7.17(p<0.001) 
4.89(p<0.001) 
4.52(p<0.001) 
1.7382(p>0 05 
3.35(p<0 01) 
3.22(p<0.01) 
4.32 (p<0.001) 
1.195 (p>0.05) 
2.97(p<0.01) 
1.95(p>0.05) 
5.116 (p<0.001) 4.67(p<0.001) 
4.90(p<0.001) 
9.36(p<0.001) 
4.21(p«=0.001) 
4.25(p<0.001) 
4.85 (p<0 001) 
3.87(p<0.0l) 
2.210 (p<0.05) 
2.16(p<0.05) 
3.64(p<0.01) 
4.59(p<0.001) 
2.36(p<0.05) 
3.76(p<0.01) 
3.87(p<0.01) 
2.96(p<0.01) 
2.84(p<0.05) 
3.10(p<0.01) 
4 02(p<0.01) 
6.46(p<0.001) 
4.58(p<0.001) 
5.26 (p<0.001) 
4.99(p<0.001) 
5.13(p<0.001) 
4.75(p<0.001) 
1.87(p>0.05) 
2.10(p>0.05) 
2.91 (p<0.05) 
2.10(p<0.05) 
2.93(p<0.01) 
2C5(p>0.05) 
5.62(p<0.001) 
9.18(p<0.001) 
3.52(p<0.01) 
4.4(p<0.001) 
3.01 (p<0.01) 
2.67(p<0.05) 
3.39(p<0.01) 
2.92(p<0.01) 
3.57(p<0.01) 
2.19(p<0.05) 
3.04(p<0.0l) 
3.69(p<0.01) 
3.60(p<0.01) 
1.89(p>0.05) 
4.55(p<0.001) 
3.20(p<0.01) 
2.12(p<0.05) 
2.91 (p<0.01) 
6.45(p<0.001) 
5.85(p<0.001) 
4 42(p<0.001) 
7.23(p<0.001) 
4.75 (p<0.001) 
4.63(p<0.001) 
4.78 (p<0.001) 
4.68(p<0.001) 
1.7(p>0.05) 
1.52(p>0.05) 
0.97(p>0.05) 
N.B. : No further analysis for these 
items carried out as no significant 
difference (p>0.05) is seen between 
both the groups at respective days of 
assessment. 
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Unusual 
thought content 
Uncooperative-
ness 
Blunted 
affect 
Depression 
7 
14 
28 
0 
7 
14 
28 
0 
7 
14 
28 
0 
7 
14 
28 
4.07±2.8 
2.4±2.1 
1.S±1.4 
2.93±2 
2±1.7 
1.36±1.7 
1±0 
1.87±1.5 
2.53±1.6 
2.2±1.5 
1,47±0.6 
3.47±3.5 
2.87±2.8 
2.33±2.7 
1.8*1.2 
TABLE 7 (CONTD..) 
3.5±3 
1.27±0.7 
1.26±0.2 
2.9±18 
1.73±0.9 
1±0 
1±0 
2±1.4 
1.93±0.9 
1.93±0.8 
1.4±0.5 
2.93±3.2 
1.7311.3 
1.33±0.6 
1.53±0.8 
0 50(p>0.05) 
1.98(p>0.05) 
0.65(p>0.05) 
0.04 (p>0.05) 
0.51 (p>0.05) 
0.86(p>0.05) 
0(p>0.05) 
0.25(p>0.05) 
1.25(p>0.05) 
0.59(p>0.05) 
0.35(p>0.05) 
0.44(p>0.05) 
1.43(p>0.05) 
1.37(p>0 05) 
0.69(p>0.05) 
p>0.05, not significant, *p<0.05 & *p <0.01 is significant 8. *p<0.001 is highly significant. 
from the HAL group; Subjects in HAL group at 
baseline assessment (day 0) have significantly 
(p<0.05) less ANXIETY than those in RIS group. 
Subsequently there is no significant difference 
at day 7, 14 & 28. For all the other items 
comprising the dimensions of Psychopathlogy 
in the BPRS, no significant difference in scores 
(p>0.05) between the two groups are found at 
the respective days of assessment. 
Table 7b shows the comparison of scores 
for individual items between respective days of 
assessment in HAL & RIS group and indicate 
that, for HALLUCINATORY BEHAVIOUR the 
improvement is highly significant (p<0.001) in 
both HAL & RIS group between the days - day 0 
& 7, day 0 & 14 & day 0 & 28. In both the groups 
the improvement between day 0 & 14 is more 
significant (p<0.001) than between day 14 & 28 
(p>0.05, not significant). Analysis of HOSTILITY 
indicate that in both the groups there is significant 
improvement (p<0.01) between day 0 & 7 & day 
0 & 14. In HAL group the improvement between 
day 0 & 28 is significant (p<0.01) while in RIS 
group it is highly significant (p<0.001) between 
day 0 & 28. There is significant improvement 
(p<0.01) in both the groups between day 0 & 14 
while between day 14 & 28 there is no significant 
change in scores (p>0.05) in both the groups. 
Analysis of SUSPICIOUSNESS indicate that in 
both the groups the rate of improvement is highly 
significant (p<0.001) between day 0 & 7, d-ay 0 
& 14 & day 0 & 28. In HAL group the rate of 
improvement between day 7 & 14 is highly 
significant (p<0.001) whereas in RIS group it is 
less significant (p<0.01). The rate of 
improvement in HAL group between day 14 & 
28 is more significant (p<0.001) than what it was 
in RIS group (p<0.01). Analysis of EMOTIONAL 
WITHDRAWAL indicate that in HAL group there 
is significant worsening of symptoms (p<0.01) 
between day 0 & 7 followed by significant 
improvement (p<0.01) between day 7 & 14. The 
improvement between day 0 & 14 & day 14 & 
28 is similarly significant (p<0.05). While in RIS 
group, there is significant improvement between 
day 0 & 7 (p<0.05), day 0 & 14 (p<0.01) & day 0 
& 28 (p<0.01), the improvement between day 7 
& 14 is more significant (p<0.01) than between 
day 0 & 7 (p<0.05). The improvement in the last 
two weeks of protocol i.e. between day 14 & 28 
is similarly significant (p<0.01) as that present 
in the first two weeks of protocol (p<0.01). 
Analysis of MOTOR RETARDATION indicate 
that in HAL group, there is significant worsening 
(p<0.0!) between day 0 & 7. Thereafter, there is 
significant improvement (p<0.01) between day 
0 & 14 & day 0 & 28 & also between day 7 & 14 
(p<0.05). The rate of improvement in the first 
two weeks & last two weeks of protocol are both 
similarly significant (p<0.01). In RIS group there 
is significant worsening of motor retardation 
between day 0&7(p<0.01), day 0& 14 (p<0.01). 
But between day 0 & 28 the worsening is not 
significant (p>0.05). Results also indicate highly 
287 BUOY PRATIM CHAUDHURI et al. 
significant worsening between day 7 & 14 
(p<0.001) while significant improvement is seen 
between day 14 & 28 (p<0.05). Analysis of 
ANXIETY indicate that in the HAL group the rate 
of improvement is highly significant (p<0.001) 
when comparisions are made, while in RIS 
group, the rate of improvement is less significant 
between day 0 & 7 (p<0.01) than the highly 
significant improvement (p<0.001) seen between 
day 0 & 14, day 7 & 14, day 14 & 28 & day 0 & 
28. Analysis of GUILT, in the HAL group indicate 
no significant change in score between day 0 & 
7 (p>0.05), while between day 0 & 14 & day 0 & 
28, significant improvement is seen (p<0.05). 
The improvement is also significant between day 
7 & 14 (p<0.05), while no significant 
improvement has taken place between day 14 
& 28 (p>0.05). In RIS group, highly significant 
improvement (p<0.001) is seen between day 0 
& 7, day 0 & 14 & day 0 & 28, while no significant 
, improvement (p>0.05) has taken place between 
day 7& 14 & day 14 & 28. 
DISCUSSION 
Our findings suggest that Risperidone is 
of comparable efficacy to Haloperidol in the 
overall improvement of clinical symptomatology 
in Acute Psychosis, which is corroborated by 
Grant & Filton (1994), Min et al. (1993) and 
Umbricht& Kane (1995). 
The findings of significant improvement of 
'Thinking Disturbance' and 'Hallucinatory 
Behaviour' by Day 14 in the Risperidone group, 
suggests the superiority of Risperidone over 
Haloperidol in positive symptoms in Acute 
Psychosis during the early phase of treatment. 
This efficacy has also been advocated by 
Cardonix et al. (1995) and McEvoy (1994). 
Our findings of early response to 'Hostility' 
and 'Suspiciousness' in the subscale of "Hostile 
Suspiciousness in the RIS group, has been 
reported earlier by Czober et al.(1995), who 
suggested Risperidone's greater selective 
efficacy on Hoslitity when compared to 
Holoperidol and Placebo and said this suggests 
encouragement in the use of Risperidone as a 
treatment for patients showing frequent physical 
aggression. A different pharmacological 
mechanism of action of Risperidone, rather than 
only 5HT2. A & weak D2 blockage may be 
responsible for this outcome (Meltzer 1995). 
Worsening of, 'Withdrawal Retardation' in 
general and 'Emotional Withdrawal' a 
component of 'Withdrawal Retardation' in 
particular by Day 7 in the HAL group, contrary 
to the effectivity of Risperidone for the same 
symptomatology has also been reported by 
Cardonix (1995), Marder & Meilbach (1994) and 
Daradkeh et al. (1996). All these authors 
suggested the effectivity of Risperidone in 
negative symptoms. 
The use of trihexyphenidyl for 
Extrapyramidal symptoms in 40% of subjects in 
RIS group by Day 28, is similar to the findings of 
Emsley et al.(1995) who concluded that the risk 
of EPS in the first episode Schizophernic 
patients treated with Risperidone is considerably 
higher (close to 60%) than earlier studies, but is 
still significantly less than in a control group 
treated with Haloperidol. We used 
trihexyphexnidyl in 100% of subjects in the HAL 
group by Day 28. Owens (1994) and Min et al. 
(1993) too concluded that the severity of EPS in 
the RIS group is significantly less than in the 
HAL group. We can suggest that early worsening 
of 'Motor Retardation' a component in the 
subscale of 'Withdrawal Retardation' in HAL 
group as well as in the RIS group is because of 
the development of EPS, and subsequent 
recovery at the end of the protocol can also be 
attributed to the use of trihexyphenidyl. 
The rate of improvement of 'Guilt' suggest 
the efficacy of Risperidone in depressive 
symptoms. According to Abel et al. (1977) 
depressive symptoms in Schizophrenia maybe 
related to the overactivity of 5HT2 A/2C receptors 
and drugs which block this receptor might be 
useful in the treatment of these symptoms. 
The highly significant rate of improvement 
of'Anxiety' in the 'Anxious Depression' subscale 
in the HAL group, can be attributed to the 
anxiolytic effect of Haloperidol. However to be 
fair, Kaplan and Sadock (1994) suggest use of 
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low dosages of Haloperidol in the treatment of 
anixety disorder, although this efficacy is to be 
weighed against the potential risk of 
Extrapyramidal side effects. 
We can conclude that Risperidone at 4mg/ 
day has an overall therapeutic activity comparable 
to Haloperidol 15 mg/day on outcome of clinical 
symptomatology at short term in first episode 
Acute and transient psychotic disorder with 
Risperidone holding a more efficacious and early 
onset of action on some of the positive & negative 
symptoms in comparison to Haloperidol. We feel 
that it may represent a potentially useful first line 
antipsycthotic agent in the treatment of Acute 
Psychosis in their first episodes.' 
ACKNOWLEDGEMENT 
Dr. Kangan Pathak, MD, Resident Phsycian, 
Department of Psychiatry, Gauhati Medical College 
& Hospital, Guwahati - 781 032, Assam. 
REFERENCES 
Abel.K.M., O'Keane.V., Murray,R.M. & 
Cleare.A.J. (1977) Serotonergic function & 
Negative & Depressive symptomatology in 
Schizophrenia & Major Depression. 
Psychoneuroendocrinology, 22, 539-48. 
Adityanyee & Pelonero.A.L. (1995) 
Prescribing Risperidone. Psychiatric Serv., 46, 
291-292. 
Anderson,W.H., Kuehrrle.J.C. & 
Catanzano.D.M. (1976) Rapid Treatment of 
Acute psychosis. American Journal of Psychiatry, 
133, 1076-1078. 
Buckley.P.F. (1997) New Dimensions in 
the Pharmacologic treatment of Schizophrenia 
and Related Psychoses. J. Clin. Pharmacol., 37: 
363-378. 
Cardonix (1995) Risperidone : Review 
and Assessment of its role in the treatment of 
Schizophrenia. Ann Pharmacotherapeutic (June) 
29, 65610-65618-
Czobor.P., Volavka.J. & Meilbach.R.C. 
(1995) Effect of Risperidone on Hostility in 
Schizophrenia. J. Clin. Psychopharmacol., Aug., 
15,4,243-249. 
Danik.J.J. & Goverdhan,M. (1963) 
Haloperidol in the treatment of 120 Psychotic 
patients. American Journal of Psychiatry, 12,39,391. 
Daradekh.T.K., Reda.F. & Karim.L. 
(1996) Efficacy & Safety of Risperidone in 
Psychotic Patients : an open study. J. Int. Med. 
Res., 24, 3, 291-295. 
Emsley.RA, McCreadie.R. & Livingstone, 
M. (1995) Risperidone in the treatment of first 
episode patients with schizophreniform disorder 
a double blind multicenter study. Presented at 
the American Psychiatric Association 148th 
Annual Meeting, Miami. 
Fitegerald.G.H. (1969) A double-blind 
comparison of Haloperidol with Fluphenazine in 
acute psychotic episodes. Current Therapeutic 
Research, 11, 515- 519. 
Grant.S. & Filton.A. (1994) Risperidone: 
A review of its pharmacology & Therapeutic 
potential in the treatment of Schizophrenia. 
Drugs, 48, 2, 253-273. 
Janssen.P.A.J., Niemegers.C.J.E., 
Awouthers.R, Schellakens.K.H.L., Megens, 
A.A.H.P. & MeertT.F. (1988) Pharmacology of 
Risperidone (R 64 766), a new antipsychotic with 
serotonin S2 and dopamine D2 antagonistic 
properties. Journal of Pharmacology and 
Experimental Therapeutics. 244, 685-693. 
Johnson.D.A.W. (1995) Peer Review of 
'Risperidone in the treatment of patients with 
chronic Schizophrenia ; a multinational, 
multicenter, Double-blind, parallal - group study 
versus Hatopeodol'. British Journal of Psychiatry, 
165, 727-753. 
Kammen.D.P.V. & Marder.S.R. (1995) 
Dopamine Receptor Autagonist. In 
289 BUOY PRATIM CHAUDHURI ef a/. 
Comprehensive Textbook of Psychiatry, Vol.2, 
Edn.6, (Eds.) Kaplan,H.I. & Sadock.B.J., pp. 
1987-2022. 
Kane.J.M. (1994) Risperidone (editorial). 
American Journal of Psychiatry, 151,6, 802- 803. 
Kaplan.H.I., Sadock.B.J. & Grebb.JA 
(1994) Dopamine Receptor Antagonists. In : 
Kaplan and Sadock Synopsis of Psychiatry, Edn. 
7, (Eds.) Kaplan.H.I. & Sadock.B.J., pp. 940-960, 
Baltimore : Williams & Wilkins. 
Risperidone in the treatment of Schizophrenia. 
American Journal of Psychiatry, 151, 6, 825-835. 
McEvoy.J.P. & Hogarty.G.E. (1991) 
Steingars : Optimal dose of Neuroleptic in 
acute Schizophrenia : A controlled study of 
the neuroleptic threshold and higher haloperidol 
dose. Archives of General Psychiatry, 48,739-745. 
McEvoy,J.P.(1994) Efficacy of risperidone 
on positive features of Schizophrenia. Journal 
of Clinical Psychiatry, ISSN : 0160 - 6689. 
Khanna.A., Lal.N., Dalai,P.K., Khalid,A. 
& Trivedi.J.K. (1997) Treatment of Acute & 
Transient Psychotic Disorders with low & high 
doses of oral Haloperidol. Indian Journal of 
Psychiatry, 39,2, 136-142. 
Kopaia.L.C. (1997) Clinical Experience 
in developing treatment regimens with the novel 
antipsyshotic risperidone. Int. Clin. 
Psychopharmacol (England), 12, (supp4), 11-8. 
Leysen.J.E., Gommeren.W., Eens.A., 
DeChaffoy, De Courselles.D., Stoof.J.C. & 
Janssen,P.A.J. (1988) Biochemical profile of 
risperidone, a new antipsychotic. Journal of 
Psychopharmacology and Experimental 
Therapeutics, 247, 661-670. 
Lieberman.J., Jody.D., Geisler.S., 
Alvir.J., Loebel.A., Szymanski.S., Woerner.M., 
Borenstein.M. (1993) Time Course & Biological 
Correlates of treatment response in first episode 
schizophrenia. Archives of General Psychiatry, 
50, 369-376. 
Marder.S.R. & Meilbach.R.C. (1994) 
Meltzer.H.Y. (1995) The role of Serotonin 
in Schizophrenia & the place of serotonin-
dopamine antagonist antipsychotics. J. Clin. 
Psychopharmacol, 15, (suppl. 1), 25-35. 
Min.S.K., Rhee.C.S., Kim.C.E. & Kang, 
D.Y. (1993) Risperidone versus haloperidol in 
the treatment of chronic schizophrenic patients: 
a parallel group double-blind comparative trial. 
Younsei - Med Journal, (June), 34, 2, 179-190. 
Mountain, H.E. (1963) Crash 
tranquilisation in a milieu therapy setting. Journal 
of Fort Logan Health Centre, 1, 43-44. 
Overall.J. & Gorham.D. (1962) Brief 
Psychiatric Rating Scale. Psychol Rep., 10, 799. 
Owens.D.G. (1994) Extrapyramidal side 
effects & tolerability of Risperidone : A Review. 
Journal of Clin. Psychiatry, (May), 55, (Suppl), 
29-35. 
Umbricht.D. & Kane.J.M. (1995) 
Risperidone : Efficacy and Safety. Schizophr. 
Bull., 21,4. 593-606. 
BUOY PRATIM CHAUDHURI', MBBS. Post Graduate Student. Department of Psychiatry, Gauhati Medical College & Hospital, 
Guwahati. ZiakurHouse. R.K. ChaudhunRoad, Bharalumukh, Guwahati-781 009, DIPESHBHAGABATI. MD, DPM, Professor, 
Department of Psychiatry, Gauhati Medical College & Hospital. Guwahati, Ganesh Mandir Road, New-Guwahati, P.O. Noonmati, 
Guwahati - 781 020, DIPANJALIMEDHI, Post Graduate Student, Department of Psychiatry, Gauhati Medical College & Hospital, 
Guwahati-781 032. 
* Correspondence 
290 